Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA RECALLS & COURT ACTIONS: Sept. 16 & 23, 1992

Executive Summary

CLASS I -- CLOZARIL (CLOZAPINE) 100 mg SandoPak (unit dose pack), 100 tablets, a Rx anti-psychotic drug. Recall number: D-497-2. All lots on the market as of 7/31/92. Manufacturer: Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey. Recalled by: Manufacturer, by letters dated July 24 and 31, 1992. Firm-initiated field correction ongoing. Distribution: Nationwide; firm estimates 1,000 SandoPaks remain on the market. Reason: Some blister cavities of the unit dose strips contained two tablets instead of one. CLASS II -- (a & b) ENGLISH PLANTAIN ALLERGENIC EXTRACT; (c) CUSTOM WEED MIX ALLERGENIC EXTRACT (a) In 50 ml vials; (b) in 30 ml vials; (c) in 50 ml vials. Recall number: B-330/332-2. Lot numbers: 54-68-2A1; (b) 54-68-2A2; (c) P0275-70-1A1. Manufacturer: Greer Laboratories, Inc., Lenoir, North Carolina. Recalled by: Manufacturer, by telephone May 7, 1992. Firm- initiated recall complete. Distribution: North Carolina, South Carolina, Connecticut, Oregon, Kentucky, Florida, Kansas, Texas; (a) 19 vials; (b) 1 vial; (c) 1 vial. Firm estimates none remains on the market. Reason: Allergenic extracts, labeled with the incorrect type of allergen, were distributed. CLASS II -- RITALIN (METHYLPHENIDATE HCl) 20 mg, 100 tablets, a Rx product for oral administration as a central nervous system stimulant. Recall number: D-498-2. Lot numbers: 1B005856 EXP 11/96, 2B005856 EXP 11/96, 1B006379 EXP 12/96. Manufacturer: Ciba-Geigy Corporation, Pharmaceutical Division, Summit, New Jersey. Recalled by: Manufacturer, by letter July 14, 1992, followed by telephone. Firm-initiated recall ongoing. Distribution: Nationwide and international; 28,476 units of lot 1B005856, 6,814 units of lot 2B005856, and 33,354 units of lot 1B006379 were distributed; firm estimates 20,500 units remain on the market. Reason: An incorrect National Stock Number (NSN) intended for Ritalin-SR 20 mg was an error printed on the Ritalin 20 mg label. CLASS II -- Rx SMALL VOLUME PARENTERALS IN PREFILLED SYRINGES (a) Heparin Lock Flush Solution, USP, 100 units/ml, in 3 ml syringes, catalog number 10773 and 5 ml syringes, catalog number 10775, with the 3 ml syringe also packaged in the Lok-Pak-N Heparin Lock Flush Procedure Pack, catalog number 11873; (b) Sodium Chloride Injection, USP, 0.9%, Preservative Free, in 2 ml syringe, catalog number 11272, packaged in the Lok-Pak-N Heparin Lock Flush Procedure pack, catalog number 11771. Recall number: D-495/496-2. Lot numbers: (a) 91M003B (5 ml), 91M004D (3 ml), 91M004C (Kit number 11873); (b) 91M002 (2 ml), 91M001B (kit number 11771). Manufacturer: Smith & Nephew SoloPak, Franklin Park, Illinois. Recalled by: Smith & Nephew SoloPak, Elk Grove Village, Illinois, by letters dated Aug. 18, 1992. Firm-initiated recall ongoing. Distribution: Nationwide; (a) 55,560 3-ml syringes, 115,200 3-ml syringes in kits, and 92,280 5-ml syringes; (b) 163,320 2-ml syringes in kits were distributed; firm estimates that 10 percent of the product remains on the market. Reason: Lack of assurance of sterility. CLASS II -- VARIOUS LYPHOMED Rx INJECTABLE DRUG PRODUCTS (a) Aminophylline Injection, USP, 25 mg/ml, in 20 ml vials; (b) Atropine Sulfate Injection, USP, 0.5 mg/ml, in 1 ml vials; (c) Cyanocobalamin Injection, USP, 1,000 mcg/ml, in 1 ml vials; (d) Diazepam Injection, USP, 5 mg/ml, in 2 ml vials; (e) Heparin Lock Flush Solution, 10 USP units/ml, in 1 ml vials; (f) Heparin Sodium Injection, USP, 10,000 USP units/ml, in 1 ml vials; (g) Lidocaine HCl Injection, USP, 2%, 20 mg/ml, in 2 ml vials; (h) Mannitol Injection, USP, 25%, 250 mg/ml, in 50 ml vials; (i) Multilyte-20 Multi-Electrolyte Concentrate, in 25 ml vials; (j) Phenytoin Sodium Injection, USP, 50 mg/ml, in 2 ml and 5 ml vials; (k) Potassium Chloride for Injection Concentrate, USP, Preservative Free, 2 mEq/ml, in 10 ml vials, and in 20 ml vials; (l) Potassium Chloride for Injection Concentrate, USP, 2 mEq/ml, preserved, in 20 ml vials; (m) Pyridoxine Hydrochloride Injection, USP, 100 mg/ml, in 1 ml vials; (n) Sodium Chloride Injection, USP, 23.4%, in 30 ml vials; (o) Sterile Water for Injection, USP, in 5 ml vials, 50 ml vials, and 100 ml vials; (p) Thiamine Hydrochloride Injection, USP, 100 mg/ml, in 2 ml vials. Recall number: D-503/518-2. Lot numbers: (a) 320114, 320290, 320291; (b) 311244; (c) 311250, 320371; (d) 320324; (e) 311199, 311210, 311307, 320024, 320120, 320186, 320158, 320168, 320208, 320214, 320354, (f) 311213, 311299, 311302, 320105, 320111, 320195, 320451; (g) 311238; (h) 310131, 310133, 310132, 310968, 320012, 320011; (i) 320344; (j) 311288, 320044, 320129; (k) 311277, 320078, 311248, 320072, 320312; (l) 311340; (m) 311245, 320155; (n) 320403, 320185; (o) 311366, 320172, 311258, 320322; (p) 320159, 320331. Manufacturer: Lyphomed, Division of Fujisawa USA, Inc., Grand Island, New York. Recalled by: Lyphomed, Division of Fujisawa USA, Inc., Melrose Park, Illinois, by letter Aug. 28, 1992. Firm- initiated recall ongoing. Distribution: Nationwide, The Bahamas, Nicaragua, Hong Kong, Peru, Malta. Vials distributed/estimated to remain on market: (a) 87,100/43,450; (b) 56,250/11,250; (c) 233,150/47,295; (d) 88,790/48,660; (e) 1,927,625/269,868; (f) 1,448,150/260,667; (g) 42,350/4,930; (h) 124,775/36,491; (i) 8,750/4,275; (j) 108,182/59,540; (k) 292,800/38,521; (l) 53,150/6,798; (m) 77,325/31,199; (n) 86,475/24,213; (o) 116,325/29,994; (p) 119,975/48,306. Reason: The vials have a low fill volume. CLASS II -- VARIOUS Rx AND OTC DRUG PRODUCTS REQUIRING REFRIGERATED STORAGE CONDITIONS (a) Repository Corticotropin Injection, USP, ACTH, in 5 ml vials: (i) 40 units/ml, Major item number 179606; (ii) 80 units/ml, Major item number 184143; (b) Major Naphazole A Ophthalmic Solution, Naphazoline HCl 0.025% and Pheniramine Maleate 0.3% Ophthalmic Solution, USP (Sterile), in 15 ml dropper container, Major item number 135418; (c) Major Sulfacetamide Sodium Ophthalmic Solution, USP, 10% (Sterile), in 15 ml bottle, Major item number 129155; (d) Acetaminophen Suppositories: (i) Mapap Pediatric Rectal Suppositories, Acetaminophen 120 mg, 12 suppositories per box, Major item number 127449, M-11 on box; (ii) G & W Acephen Acetaminophen Rectal Suppositories, Acetaminophen 325 mg, 12 suppositories per box, Major item number 184200; (iii) Mapap Rectal Suppositories, Acetaminophen 650 mg, 12 suppositories per box, Major item number 127464, M-11 on box; (e) G & W Truphylline Aminophylline Suppositories, 500 mg, 10 suppositories per box, Major item number 184150; (f) Major Phenameth Promethazine HCl Suppositories, 50 mg, 12 and 25 suppositories per box, Major item number 153866; (g) Major Erythromycin Ethylsuccinate Oral Suspension, in 1 pint bottles: (i) 200 mg/5 ml: Major item number 140293; (ii) 400 mg/5 ml: Major item number 140301; (h) Major Erythromycin Estolate Oral Suspension, USP, in 1 pint bottles, store in refrigerator to preserve taste: (i) 125 mg/5 ml: Major item number 140319; (ii) 250 mg/5 ml: Major item number 140335. Recall number: D-482/494-2. Code: Ellis Division Ormond Beach, FL, Woburn, MA and Winston Salem, NC locations: All products, all lots within expiration date; Murray Division, Murray, KY and Houston, TX locations: items a, b, c, g, h; all lots within expiration date; Crown Division Chicago, IL and Omaha, NE locations: items b, e, f (12's): All lots; item c, lot number 0693 and 0398 only; item g -- ii, lot number 0020 only; item a -- i, all lots, Omaha customers only; Michigan Division, Auburn Hills, MI location: item b, lot 0874 only; item d -- ii, all lots; item h -- ii, lot number 13097 only; Ultra Division, Seattle, WA and San Diego, CA locations: items b, f: all lots; item c, all lots for Seattle and lot 9764 only for San Diego. Manufacturer: (a) Organics/LaGrange, Chicago, Illinois; (b, c, g) Pharmafair, Inc., Tampa, Florida; (b, c) Bausch & Lomb Pharmaceuticals, Clearwater, Florida; (d, e, f) G & W Laboratories, Inc., South Plainfield, New Jersey; (g, h) Barre- National, Inc., Baltimore, Maryland. Recalled by: Major Pharmaceuticals, Chicago, Illinois (responsible firm), by letter Aug. 25, 1992. Firm-initiated recall ongoing. Distribution: Nationwide; 189 vials of 40 u/ml and 417 vials of 80 u/ml repository corticotropin; 10,540 bottles of Naphazole A; 48,011 bottles of Sulfacetamide; 1,108 125-mg, 420 325-mg, & 1,119 650-mg boxes of acetaminophen suppositories; 214 boxes of aminophylline suppositories; 801 X 12 and 121 X 25 boxes of promethazine HCl suppositories; 713 200-mg and 562 400-mg bottles of erythromycin ethylsuccinate; and 168 125-mg and 495 250-mg bottles of erythromycin estolate were distributed which had not been refrigerated. The firm estimates that 10% of the product remains on the market. Reason: The products were not held at the labeled storage temperatures, which could affect the products' potency and/or physical properties. CLASS III -- BEN-AQUA GEL 5% (BENZOYL PEROXIDE 5%) In 4 ounce tubes. Recall number: D-499-2. Lot number H282 EXP 12/93. Manufacturer: Syosset Laboratories Company, Inc., Syosset, New York. Recalled by: Manufacturer, by letter Aug. 6, 1992, followed by telephone Aug. 7, 1992. Firm-initiated recall ongoing. Distribution: California, New Mexico, Minnesota, New York, New Jersey; 918 units were distributed. Reason: Some tubes have leakage at the crimp. CLASS III -- (a) THORAZINE; (b) THORAZINE SYRUP (Chlorpromazine Hydrochloride) Concentrate 30 mg/ml, in 4 fluid ounce bottles; (b) 10 mg/5 ml in 4 fluid ounce bottles. Recall number: D-501/502-2. Lot numbers: (a) X1-1T47 EXP 6/30/95; (b) X3- 0T72 EXP 11/30/93, X4-0T72 EXP 11/30/93, X5-0T72 EXP 11/30/92, X6- 1T72 EXP 9/30/94, X7-1T72 EXP 9/30/94, X8-1T72 EXP 9/30/94, 2-2T72 EXP 2/28/95, 3-2T72 EXP 3/31/95. Manufacturer: SmithKline Beecham Pharmaceuticals Company, Cidra, Puerto Rico. Recalled by: Manufacturer, by letter mailed Aug. 11, 1992. Firm-initiated recall ongoing. Distribution: Nationwide; (a) 4,120 bottles were distributed; firm estimates none remains on the market; (b) 35,905 bottles were distributed; firm estimates 4,000 bottles remain on the market. Reason: (a) Product does not meet pH specifications; (b) Potency not assured if continuously stored at upper temperature limit. CLASS III -- TRIAMCINOLONE ACETONIDE CREAM 0.1%, 80 gram size. Recall number: D-500-2. Lot number H208 EXP 10/93. Manufacturer: Syosset Laboratories Company, Inc., Syosset, New York. Recalled by: Manufacturer, by letter Aug. 13, 1992. Firm- initiated recall ongoing. Distribution: Florida, Illinois; 1,208 tubes were distributed. Reason: Some tubes have leakage at the crimp. CLASS III UPDATE -- IBUPROFEN TABLETS Ibuprofen Tablets, Recall number: D-456-2. Manufactured by: Boots Pharmaceuticals, which appeared in the Aug. 19, 1992 Enforcement Report ("The Pink Sheet" Aug. 31, T&G-12) is the Rx drug.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel